Core Viewpoint - Regend Therapeutics Limited has completed a C round financing of 350 million RMB, with funds aimed at advancing clinical applications of stem/progenitor cell products [3][8]. Group 1: Company Overview - Regend Therapeutics, founded in 2015, focuses on regenerative medicine using progenitor cells for organ repair and enhancement [3][4]. - The company is led by founder Zuo Wei, a PhD in cell biology from Tsinghua University, and CEO Zhang Ting, a PhD in biology from Tsinghua University [3]. Group 2: Product Pipeline - The core pipeline includes REGEND001 (autologous lung progenitor cells) and REGEND003 (autologous kidney progenitor cells), both of which are in clinical stages targeting chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and chronic kidney disease (CKD) [4][6]. - REGEND001 aims to regenerate healthy alveoli to improve lung function, with significant improvements observed in clinical trials compared to control groups [6][7]. - REGEND003, targeting diabetic kidney disease (DKD), utilizes a non-invasive method to obtain kidney progenitor cells from urine, showing promising preclinical results [7]. Group 3: Clinical Trials and Milestones - REGEND001 is set to initiate Phase 3 clinical trials in China in 2026 for COPD and IPF, with ongoing discussions with regulatory authorities [6]. - The product has already been approved for clinical transformation in the Boao Lecheng International Medical Tourism Pilot Zone, with over 140 treatments completed since May [7]. Group 4: Investment and Strategic Plans - The completion of the C round financing will support clinical advancement, international strategy, commercialization, and talent acquisition [8]. - The company plans to establish at least two regional production centers across China to enhance production capacity for clinical products [8]. Group 5: Investor Perspectives - Investors view Regend Therapeutics as a leading innovator in the regenerative medicine sector, with significant clinical progress and a strong competitive advantage [8][9]. - The company’s advancements in progenitor cell technology and successful clinical trials for COPD and IPF have garnered positive investor sentiment [9].

Core Insights - Regend Therapeutics Limited has completed a C-round financing of 350 million RMB, with new investors including Yuze Capital and Hefei High-tech Investment, among others, and existing investors continuing to support the funding [1] - The funds will be used to advance clinical applications of core products related to stem/progenitor cells [1] Company Overview - Founded in 2015, Regend Therapeutics focuses on regenerative medicine using progenitor cells to repair and enhance human organs through innovative cell gene therapy products [1] - The company is led by founder Zuo Wei, a PhD in cell biology from Tsinghua University, and CEO Zhang Ting, a PhD in biology from Tsinghua University [1] Product Pipeline - Regend's core pipeline includes REGEND001 (autologous lung progenitor cells) and REGEND003 (autologous kidney progenitor cells), both of which have entered clinical stages [1][2] - REGEND001 targets chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), with clinical trials showing significant improvements in lung function and quality of life [3] - REGEND003 aims to treat diabetic kidney disease (DKD) and has received approval for Phase I clinical trials, utilizing a non-invasive method to obtain kidney progenitor cells from urine [4] Clinical Development and Commercialization - Regend plans to initiate Phase III clinical trials for REGEND001 in 2026, focusing on COPD and IPF, and has received orphan drug designation from the FDA for IPF [3] - The company has already begun clinical transformation and commercialization of its therapies in the Boao Lecheng International Medical Tourism Pilot Zone, with over 140 cases completed since last May [4][5] Investor Perspectives - Investors view Regend as a leading innovative company in the regenerative medicine sector, with a strong competitive advantage and a clear path to commercialization [6][7] - The completion of the C-round financing is expected to support clinical advancement, international strategy, and the establishment of a commercial system [6]